Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00266358PMID 1577054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Hypertension and hyperuricemia].

  1996cited by this paper
• Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.

  1990cited by this paper
• Nonpeptide Angiotensin II Receptor Antagonists: Studies With EXP9270 and DuP 753

  1990cited by this paper
• Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.

  1990cited by this paper
• Angiotensin II: a powerful controller of sodium transport in the early proximal tubule.

  1990cited by this paper
• Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist.

  1990cited by this paper
• Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.

  1990cited by this paper
• Uricosuric diuretics.

  1980cited by this paper
• Serum uric acid in essential hypertension: an indicator of renal vascular involvement.

  1980cited by this paper
• Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system.

  1980cited by this paper
• Hyperuricemia in primary and renal hypertension.

  1966cited by this paper
• BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.

  1963cited by this paper

• Current Challenges and Emerging Therapies in the Treatment of Gout.

  2024cites this paper
• Uric Acid and Oxidative Stress—Relationship with Cardiovascular, Metabolic, and Renal Impairment

  2022cites this paper
• CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study

  2022cites this paper
• New insight into the management of renal excretion and hyperuricemia: Potential therapeutic strategies with natural bioactive compounds

  2022cites this paper
• Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights

  2021cites this paper
• Losartan

  2021cites this paper
• The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia

  2021cites this paper
• Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound

  2018cites this paper
• Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.

  2017cites this paper
• Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

  2016cites this paper
• The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

  2016cites this paper
• Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis

  2015cites this paper
• The molecular physiology of uric acid homeostasis.

  2015cites this paper
• Acute Effects of Oral Tofisopam on Plasma Concentration and Urinary Excretion of Uric Acid and Oxypurinol "Preliminary Communication".

  2015cites this paper
• Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.

  2015cites this paper
• Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model.

  2015cites this paper
• URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia.

  2015cites this paper
• Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability

  2014cites this paper
• Metabolic Syndrome, Alcohol Consumption and Genetic Factors Are Associated with Serum Uric Acid Concentration

  2014cites this paper
• Effects on Uric Acid Metabolism of the Drugs except the Antihyperuricemics

  2014cites this paper
• Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.

  2014cites this paper
• Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy.

  2014cites this paper
• Clinical Aspects of Gout and Associated Disease States

  2013cites this paper
• Management of Hyperuricemia and Gout

  2013cites this paper
• Biomarkers and assessment of drug efficacy in cardiovascular disease

  2013cites this paper
• A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists

  2013cites this paper
• Which is a Better Treatment for Hypertensive Patients with Diabetes: A Combination of Losartan and Hydrochlorothiazide or a Maximum Dose of Losartan?

  2013cites this paper
• Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?

  2013cites this paper
• Off-target effects of RAAS-inhibition

  2012cites this paper
• Off-target effects of RAAS-inhibition: importance on renal outcomes in patients with diabetes

  2012cites this paper
• An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials

  2012cites this paper
• The pharmacokinetic-pharmacodynamic assessment of the hypotensive effect after coadministration of losartan and hydrochlorothiazide in spontaneously hypertensive rats.

  2012cites this paper
• Significant interaction between LRP2 rs2544390 in intron 1 and alcohol drinking for serum uric acid levels among a Japanese population.

  2012cites this paper
• EXPRESSION DER KOMPONENTEN DES RENIN- ANGIOTENSIN-SYSTEMS ENTLANG DES MAUSNEPHRONS

  2012cites this paper
• Efficacy and Safety of Mizoribine Combined With Losartan in the Treatment of IgA Nephropathy: A Multicenter, Randomized, Controlled Study

  2011cites this paper
• Serum uric acid distribution according to SLC22A12 W258X genotype in a cross-sectional study of a general Japanese population

  2011cites this paper
• SLC22A12 W258X FREQUENCY ACCORDING TO SERUM URIC ACID LEVEL AMONG JAPANESE HEALTH CHECKUP EXAMINEES

  2011influential citation
• Significant association of serum uric acid levels with SLC2A9 rs11722228 among a Japanese population.

  2011cites this paper
• Renal Handling of Organic Solutes

  2011cites this paper
• Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial

  2011cites this paper
• Uric acid and transplantation.

  2011cites this paper
• : A Post

  2011cites this paper
• Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA

  2010cites this paper
• Gout: the current look at diagnostics and treatment

  2010cites this paper
• Effect of fenofibrate on uric acid metabolism and urate transporter 1.

  2010cites this paper
• Reviewing the benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy--are they drug specific or class specific?

  2010cites this paper
• Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease.

  2010cites this paper
• Differences in pharmacology and their translation into differences in clinical efficacy – a comparison of the renin angiotensin blocking agents irbesartan and losartan

  2010cites this paper
• Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide

  2009cites this paper
• Efficacy of Low-Dose Hydrochlorothiazide in Combination with Telmisartan on Early Morning Blood Pressure in Uncontrolled Hypertensive Patients

  2009cites this paper
• Angiotensin II Receptor Blockers Induce Alteration of Serum Uric Acid Level via Renal Uric Acid Transporters. A Review of the Authors' Current Research

  2009cites this paper
• Assessing the effects of low dose aspirin on uricacid and renal function in healthy adults

  2009cites this paper
• Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker.

  2009cites this paper
• Involvement of Uric Acid Transporters in Alteration of Serum Uric Acid Level by Angiotensin II Receptor Blockers

  2008cites this paper
• Efficacy and Safety of Long-Term Losartan Therapy Demonstrated by a Prospective Observational Study in Japanese Patients with Hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) Study

  2008cites this paper
• Clinical Efficacy of a New Angiotensin II Type 1 Receptor Blocker, Pratosartan, in Hypertensive Patients

  2008cites this paper
• Pharmacoepidemiological Study on Suppression of Hyperuricemia by Losartan

  2008cites this paper
• Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.

  2008cites this paper
• Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine

  2007cites this paper
• Drug discovery for hyperuricemia

  2007cites this paper
• Antihypertensive Efficacy and Safety of Fixed-Dose Combination Therapy with Losartan plus Hydrochlorothiazide in Japanese Patients with Essential Hypertension

  2007cites this paper
• New insights into renal transport of urate

  2007cites this paper
• Concentration-Dependent Mode of Interaction of Angiotensin II Receptor Blockers with Uric Acid Transporter

  2007cites this paper
• The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?

  2007cites this paper
• Uric acid reduction: a new paradigm in the management of cardiovascular risk?

  2007cites this paper
• Renal urate transport.

  2006cites this paper
• Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?

  2006cites this paper
• Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.

  2006cites this paper
• Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population

  2006cites this paper
• Estudio de farmacovigilancia para evaluar la seguridad y la efectividad del tratamiento con losartán: efectos a largo plazo de losartán solo o en combinación sobre la uricemia*

  2006cites this paper
• Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?

  2006cites this paper
• Possible interactions of the endothelial constitutive nitric oxide synthase genotype with alcohol drinking and walking time for high serum uric acid levels among Japanese.

  2005cites this paper
• Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.

  2005cites this paper
• Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease

  2005cites this paper
• Uric Acid Elimination in the Urine

  2005cites this paper
• Review: Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension?

  2005cites this paper
• Angiotensin II Receptor Antagonists

  2005cites this paper
• Uric acid and transplantation.

  2005cites this paper
• Uric acid elimination in the urine. Pathophysiological implications.

  2005cites this paper
• Effects of SCH27899 (Ziracin), an oligosaccharide everninomicin antibiotic, on urate kinetics in humans

  2004cites this paper
• Coronary risk factors in the elderly: their interactions and treatment.

  2003cites this paper
• Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension

  2003cites this paper
• Should we take advantage of their uricosuric properties in clinical practice ?

  2003cites this paper
• A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide.

  2003cites this paper
• Fenofibrate and losartan

  2003cites this paper
• Very-low-dose combination: a first-line choice for the treatment of hypertension?

  2003cites this paper
• Cardiovascular Drugs and Serum Uric Acid

  2003cites this paper
• Uricosuric Effects of Angiotensin II Receptor Antagonists in the Patients With Normal Renal Function

  2003cites this paper
• Antihypertensive Agents: Mechanisms of Drug Action

  2003cites this paper
• INTERNATIONAL JOURNAL OF INTERVENTIONAL CARDIOANGIOLOGY Quarterly Journal of the Russian Scientific Society of Interventional Cardioangiology

  2003cites this paper
• Atlas of Hypertension

  2003influential citation
• Association of a 27-bp repeat polymorphism in intron 4 of endothelial constitutive nitric oxide synthase gene with serum uric acid levels in Chinese subjects with type 2 diabetes.

  2003cites this paper
• Part 1. Uric acid and losartan

  2002cites this paper
• Angiotensin II receptor antagonists role in arterial hypertension

  2002cites this paper
• Uric acid and cardiovascular risk.

  2002cites this paper
• Drugs targeting the renin–angiotensin–aldosterone system

  2002cites this paper
• Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects.

  2002cites this paper
• AT1 blockers and uric acid metabolism: are there relevant differences?

  2002cites this paper
• Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients

  2002cites this paper
• Reducing uric acid as a means to prevent cardiovascular and renal disease

  2002cites this paper